During my Ph.D., my PI wanted to do some work on signalling pathway analysis. He was interested in knowing when and why sometimes body starts assuming that the sick state is the right state and start acting against drugs given to patients. This making treatment very hard.

I don't know what is status of that but one insight I got from him that most (all?) Pharma companies do not trust acdemic data. I didn't ask reasons but I'd assume because of replication issue (crisis). Knowing how data is gathered and published in signalling domain, I'd not blame them for having low trust in academic data.